| Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older (NCT05304351) | Curevo Inc | 2022-02-02 |
| Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers (NCT05245838) | Dynavax Technologies Corporation | 2022-01-10 |
| Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer (NCT04540081) | University of California, Davis | 2020-10-05 |
| Systems Biology of Zoster Vaccine (NCT04047979) | Emory University | 2019-11-14 |
| Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT (NCT04099706) | Odense University Hospital | 2019-09-19 |
| Optimal Timing of Zoster Vaccine After Zoster Illness (NCT02704572) | Seoul National University Hospital | 2016-03-01 |
| Immune Response to Shingles Vaccination (NCT02624375) | University of Washington | 2016-02-01 |
| A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia (NCT02412917) | ContraVir Pharmaceuticals, Inc. | 2015-06-01 |
| ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors (NCT02444936) | Louis Stokes VA Medical Center | 2015-05-01 |
| Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds (NCT02114333) | University of Colorado, Denver | 2014-05-01 |
| Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025) (NCT01527370) | Merck Sharp & Dohme LLC | 2012-10-31 |
| ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024) (NCT01600079) | Merck Sharp & Dohme LLC | 2012-05-15 |
| ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034) (NCT01556451) | Merck Sharp & Dohme LLC | 2012-04-01 |
| Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1) (NCT01505647) | Merck Sharp & Dohme LLC | 2012-04-01 |
| Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly (NCT01331161) | Emory University | 2011-07-01 |
| Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents (NCT01262300) | University of Colorado, Denver | 2010-11-01 |
| A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster (NCT00900783) | Bristol-Myers Squibb | 2009-05-01 |
| A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN) (NCT00576108) | Kalypsys, Inc. | 2007-11-01 |
| Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022) (NCT00534248) | Merck Sharp & Dohme LLC | 2007-10-01 |
| Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions (NCT01132716) | Roxane Laboratories | 2006-09-01 |
| Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions (NCT01132729) | Roxane Laboratories | 2006-09-01 |
| Study of NGX-4010 for the Treatment of Postherpetic Neuralgia (NCT00300222) | NeurogesX | 2006-03-01 |
| Study of NGX-4010 for the Treatment of Postherpetic Neuralgia (NCT00115310) | NeurogesX | 2005-06-01 |
| Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia (NCT00099528) | Renovis | 2003-08-01 |
| Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007) (NCT00109122) | Merck Sharp & Dohme LLC | 2001-11-01 |
| Valacyclovir in Immunocompromised Children (NCT00059592) | Baylor College of Medicine | 1998-04-07 |
| NGX-4010 for the Treatment of Postherpetic Neuralgia (NCT00061776) | NeurogesX | |